Background. The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial. Methods. After resection of pancreatic adenocarcinoma, patients were randomized to pre-and post-CRT 5-FU versus pre-and post-CRT gemcitabine. 5-FU was provided continuously at 250 mg/m 2 /day, and gemcitabine was provided at 1000 mg/m 2 weekly. Both were provided over 3 weeks before and 12 weeks after CRT. CRT was provided at 50.4 Gy with continuously provided 5-FU. The primary end point was survival for all patients and for patients with tumor of the pancreatic head. Results. Four hundred fifty-one patients were eligible. Univariate analysis showed no difference in OS. Pancreatic head tumor patients (n = 388) had a median survival and 5-year OS of 20.5 months and 22% with gemcitabine versus 17.1 months and 18% with 5-FU. On multivariate analysis, patients on the gemcitabine arm with pancreatic head tumors experienced a trend toward improved OS (P = 0.08). First site of relapse local recurrence in 28% of patients versus distant relapse in 73%. Conclusions. The sequencing of 5-FU CRT with gemcitabine as done in this trial is not associated with a statistically significant improvement in OS. Despite local recurrence being approximately half of that reported in previous adjuvant trials, distant disease relapse still occurs in C70% of patients. These findings serve as the basis for the recently activated EORTC/U.S. Intergroup RTOG 0848 phase III adjuvant trial evaluating the impact of CRT after completion of a full course of gemcitabine.
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The potential impact of gemcitabine in the adjuvant setting after resection of pancreatic adenocarcinoma has only recently been tested and reported in phase III trials. [1] [2] [3] [4] Oettle et al. had reported initially an increase in 3-year progression-free survival with the use of adjuvant gemcitabine without radiotherapy (RT). 1 This subsequently translated into an increase in overall survival (OS) at 5 years with further follow-up. 2 Reported patterns of failure analysis have demonstrated a 50% to 85% component of local tumor relapse associated with liver and/or systemic tumor relapse after resection of pancreatic adenocarcinoma. [5] [6] [7] [8] [9] This rationale for inclusion of use of RT in the postoperative adjuvant setting has been substantiated to a limited extent by phase III trials and by large institutional results. [10] [11] [12] [13] In 2008, we reported the initial results of the U.S. Intergroup phase III adjuvant trial evaluating the impact of the addition of gemcitabine to fluorouracil-based chemoradiation (CRT) after resection of pancreatic adenocarcinoma. 4 At 3 years, the addition of gemcitabine to fluorouracilbased CRT improved the median and 3-year OS in patients with resected pancreatic head adenocarcinoma at P = 0.05 on multivariate analysis. At the time of initial analysis, there was uncertainty whether this survival advantage would last over time. Therefore, we report the long-term results of this trial.
METHODS

Eligibility
This Intergroup trial was conducted by the following U.S. National Cancer Institute (NCI) sponsored cooperative groups: the Radiation Therapy Oncology Group (RTOG), the Eastern Corporative Oncology Group, and the Southwest Oncology Group, inclusive of Canadian affiliates. RTOG served as the lead group with the trial designation RTOG 97-04. The eligibility criteria included histologically confirmed adenocarcinoma of the pancreas and gross total tumor resection, confirmed by central review of patients operative and pathology reports. In addition, a postoperative computed tomographic (CT) imaging was required within 3 weeks of randomization to exclude patients who had evidence of persistent/recurrent local disease or metastatic disease before therapy. Surgical resection margins were categorized as negative, microscopically positive, or unknown (defined as those having no comment regarding margins in the pathology report). Eligibility requirements also included stages T1-4, N0-1, and M0 according to the 1997 staging criteria of the American Joint Commission on Cancer.
14 If there were no identifiable lymph nodes within the resection specimen, the patient was ineligible.
Patients were required to have a Karnofsky performance status of C60 and adequate hematologic, renal, and hepatic function as defined by the following: a white blood cell count of C3000/mm 3 , a platelet count C100,000/mm 3 , serum bilirubin and creatinine B1.5 times the upper limit of normal, a serum aspartate aminotransferase concentration B5 times the upper limit of normal, and a documented caloric intake of [1500 kcal per day. Submission of a CA19-9 serum tumor marker was required for central testing and review. Protocol therapy was required to begin 3 to 8 weeks after resection and within 5 days of randomization.
All patients required written and informed consent according to institutional and federal guidelines.
Treatment Plan
After undergoing tumor resection, patients were randomly assigned to either 5-fluorouracil (5-FU) (arm 1) or gemcitabine (arm 2) before and after CRT. Randomization was performed 3 to 8 weeks after surgery by a dynamic balancing procedure that included stratification according to tumor diameter (\3 cm vs. C3 cm), nodal status (negative vs. positive) and surgical margins (negative vs. positive vs. unknown). The pre-CRT chemotherapy in arm 1 consisted of 5-FU, 250 mg/m 2 /day, continuous infusion for 3 weeks; in arm 2, gemcitabine 1000 mg/m 2 as a 30 minute infusion once weekly for 3 weeks. Between 1 to 2 weeks after completion of pre-CRT chemotherapy, CRT was initiated and was the same for both arms. CRT consisted of 50.4 Gy with continuous infusion 5-FU, 250 mg/ m 2 /day throughout RT. Post-CRT chemotherapy was initiated 3 to 5 weeks after completion of CRT; arm 1 consisted of 3 months of continuous infusion 5-FU [(4 weeks on ? 2 weeks off) 9 2] and in arm 2, 3 months of gemcitabine [(3 weeks on ? 1 week off) 9 3]. Continuous infusion 5-FU was given 7 days each week. RT was delivered in 28 fractions, 5 days per week, to the tumor bed, and regional nodes. The tumor bed was defined by preoperative CT imaging.
Local pancreatic, celiac, mesenteric, paraortic, pancreatic, duodenal and hepatoportal lymph nodes were included in the RT fields. 15 After an initial dose of 45 Gy, the final 5.4-Gy dose was limited to the tumor bed as defined by the preoperative tumor volume. At least 4-MV photons and a minimum 3-to 4-field approach were used. Doses were limited to \60% of hepatic volume receiving [30 Gy.
At least two thirds of one functioning kidney was spared from RT fields and the spinal cord was limited to \45 Gy. Prospective quality assurance (QA) of RT was required for all. This was inclusive of submission of preoperative abdominal CT scan and RT fields to be used for central review and approval before the start of CRT.
Follow-up
First follow-up was required at 4 weeks after completion of CRT and before start of post-CRT chemotherapy. Follow-up continued to occur at 3-month intervals for 1 year, then at 6 month intervals for 2 years and then annually. Follow-up consisted of physical examination, complete blood count, liver function testing, chest x-ray, and CT scanning as clinically indicated. Elevation in CA19-9 level in and of it itself was not to be considered a criterion for disease recurrence.
Statistical Analysis
OS was the primary end point for this trial. Secondary end points were disease-free survival (DFS) and toxicity, which was scored with the U.S. NCI Common Toxicity Criteria version 2.0 for chemotherapy and the RTOG morbidity scoring scheme for RT. All end points were prespecified in the original design of the trial and all analyses were conducted on an intent-to-treat basis.
Failure for OS was defined as death due to any cause and was measured from date of randomization to date of death or last follow-up for censored patients. Failure for DFS was defined as local, regional or distant relapse, appearance of a second primary lesion or death due to any cause and measured from date of randomization to date of first failure or last follow-up for censored patients.
Local relapse was defined as recurrence at the primary resection site; regional relapse was defined as recurrence in regional lymph nodes associated with the primary resection site, and all other relapses were defined as distant. Cases that did not fail an end point were censored as of the patient's last follow-up.
Patients were stratified by nodal status (uninvolved vs. involved), tumor diameter (\3 cm vs. C3 cm) and surgical margin status (negative vs. positive vs. unknown). The permuted block randomization method was used with patient factors balanced according to the permuted block randomization method. 16 At an original expected accrual of 5 patients/month, 330 patients were targeted to detect a 33% reduction in the hazard rate of OS for the CRT ? gemcitabine arm as compared to the CRT ? 5-FU arm (increase in median survival from 18 to 27 months; hazard ratio (HR), 0.67) with 80% power and a 2-sided alpha of 0.05, assuming an exponential distribution. In early 2001, on the basis of unexpectedly rapid accrual (13 patients/month), and after approval by the U.S. Intergroup, the RTOG data monitoring committee, and the NCI, the sample size was increased to find a smaller treatment effect with more power. Four-hundred and seventy analyzable patients would provide 85% power to detect a 28% decrease in the hazard rate of OS (increase in median survival from 18 to 25 months; HR, 0.71) for all patients and 80% power in patients with pancreatic head lesions.
All analyses were performed by SAS/STAT software, version 9.2 (SAS Institute, Cary, NC). Chi-square tests were used to compare differences among pretreatment characteristics between treatment arms.
For CA19-9, the variable was categorized as \ 180 vs. C 180 to be consistent with a protocol specified CA19-9 analysis to be done subsequently and based on published literature. 17 Z tests were used to test for differences in binomial proportions of grade C2 late (defined as[90 days from the end of treatment) toxicities (worst overall, worst nonhematologic and worst hematologic).
OS and DFS were estimated univariately with the Kaplan-Meier method and treatment arms were compared by the log rank test. 18, 19 Multivariate analyses were performed with Cox proportional hazard models to test for treatment differences (between arms) while adjusting for the stratification variables of nodal involvement (no vs. yes), tumor diameter (\3 vs. C3 cm) and margin status (negative vs. positive and negative vs. unknown), as well as any other variables that were imbalanced between the treatment arms. 20 A tumor diameter of 3 cm was used for stratification based on published large institutional experience. 21 All tests were done at a significance level of 0.05. All variables are coded such that a HR [1 indicates an increased risk for the second level of the variable and a HR \1 a benefit for the second level of the variable.
RESULTS
Demographic Characteristics
Between July 1998 and July 2002, 538 patients were registered from 164 RTOG/ECOG/SWOG institutions. Eighty-six patients (16%) were ineligible for reasons previously reported and 1 patient withdrew consent. 4 Of the remaining 451 patients, 230 were randomly assigned to CRT ? 5-FU and 221 to CRT ? gemcitabine. Pretreatment factors (Table 1) were similar between groups with the exception of T stage.
The CRT ? gemcitabine arm had a higher percentage of patients with T3/T4 disease (81%) as compared to those randomized to the CRT ? 5-FU arm (70%, P = 0.013). The majority (86%) of tumors were of the pancreatic head. Sixty-six percent of patients had nodal metastases. Thirtyfour percent of patients had microscopically positive margins and 25% had pathology reports with no comment regarding the status of surgical margins (unknown).
Treatment Tolerance/Toxicity
Treatment delivery/tolerance and acute toxicity was acceptable and has been previously reported. 4 Grade 2 or higher late toxicities are summarized in Table 2 . There was no statistically significant difference in worst late nonhematologic, hematologic, or overall toxicities between the 2 arms.
Outcomes
The protocol specified that the initial treatment results be reported after either there had been 355 total deaths in both arms or there had been 190 deaths on the 5-FU containing arm. This analysis has been performed with 368 deaths, with 188 occurring on the 5-FU arm. All patients have been potentially followed for a minimum of 6.6 years.
With a median follow-up time of 1.48 years (min-max, 0.1-9.1 years) for all patients and 6.98 years (min-max, 0.3-9.1 years) for alive patients, there was no statistically significant difference in OS (Fig. 1a) or DFS between treatment arms. Although treatment crossover was not allowed, among the 230 patients in the 5-FU arm, 95 (41%) received additional salvage chemotherapy after any failure; 81% (77 of 95) received gemcitabine as salvage therapy. 13-24) on the 5-FU arm (log rank P = 0.12, HR = 0.84, 95% CI 0.67-1.05, Fig. 1b) . On multivariate analysis for pancreatic head patients, after adjusting for the protocol specified stratification variables of nodal status, which strongly effected survival (P = 0.003), tumor diameter, and surgical margin status, the treatment effect shows a trend (HR = 0.82, 95% CI 0.65-1.02, P = 0.08) toward improved OS for the gemcitabine arm (Table 3) . Although T stage was imbalanced between the arms, it was not a significant factor on multivariate analysis.
The pattern of tumor relapse was recorded as the site of the first relapse only, and these sites were categorized as local, regional, or distant (Table 4) . Eighty-nine percent (n = 205 of 230) of failures to respond to therapy occurred in disease in patients on 5-FU arm and 88% (n = 195 of 221) on the gemcitabine arm. Distribution of relapse was similar among all patients and among patients with pancreatic head tumors. Local relapse occurred in 30% of patients on the 5-FU arm and 25% on the gemcitabine arm. Regional relapse was similar on both arms at 8% vs. 7%. Distant relapse was C70% in both arms.
DISCUSSION
The 5-year results of this study demonstrate that the previously observed improvement in 3-year OS with the addition of gemcitabine to adjuvant fluorouracil-based CRT for patients with pancreatic head adenocarcinoma is no longer seen at 5 years.
Although the OS curves remain separated throughout 5 years (Fig. 1b) , only a trend toward statistical significance is now seen. Thus, in the context of this study design, any improvement in survival associated with the use of gemcitabine appears to be temporary and marginal at best.
Although the 5-year results in this study did not reach statistical significance, the observed marginal difference in survival between study arms favoring the gemcitabine arm deserves further comments in the context of the conduct and design of this trial. First, 41% of the patients on the 5-FU arm received salvage chemotherapy after any recurrence, of which 81% of patients received gemcitabine. This crossover-like occurrence may have diluted differences in survival between the 2 study arms. Secondly, a greater proportion of patients on the gemcitabine arm had T3/T4 disease (81% vs. 70%, P = 0.013).
In addition, and perhaps most importantly, an associated potential negative impact on survival benefit could be seen with gemcitabine as a result of the prolonged interruption of gemcitabine related to the fundamental design of this study. In the gemcitabine arm, patients were given a single cycle of gemcitabine, followed by a required 1-to 2-week break before initiation of 5.5 weeks of 5-FU based CRT. This was then followed by a required 3-to 5-week break to allow for recovery from acute toxicity and restaging before resumption of gemcitabine given in 3 additional cycles. Thus, between the first cycle of gemcitabine and resumption of the final 3 cycles of gemcitabine, patients were without gemcitabine therapy for at least 9.5 weeks and for as long as 12.5 weeks. Given the known exponential rate of tumor recurrence associated with this disease, this prolonged interruption of gemcitabine therapy may well have been a statistically significant factor contributing to the temporary and eventually marginal survival benefit seen with use of gemcitabine in this study.
The 5-year results from this study must also be reviewed in the context of the recently updated phase III CONKO-001 trial and the recently reported phase III ESPAC-3 trial. 2, 3 The CONKO trial randomized patients with completely resected pancreatic cancer to 6 total cycles of gemcitabine versus surgery alone. Patient selection and eligibility requirements clearly differed between RTOG 9704 and the CONKO trial, including frequency of R0 resections (42%-RTOG vs. 83%-CONKO) and the CONKO requirement for CA19-9 to be \2.5 times the upper limit of normal (*90). 22 RTOG 97-04 did not exclude patients by CA19-9, with 21% having values [90. CONKO-001 initially demonstrated only a statistically significant improvement in DFS without an improvement in OS. 1 However, the recently reported 5-year results in now demonstrate a statistically significant improvement in OS with a median and 5-year survival rate of 22.8 months and 21% in the gemcitabine arm and 20.2 months and 9% in the surgery alone arm (P = 0.005). 2 The use of 6 total cycles of gemcitabine in the CONKO trial should be viewed in contrast to our study, which in addition to the prolonged interruption of gemcitabine therapy, made use of only 4 total cycles of gemcitabine. Although the CONKO trial evaluated the impact of adjuvant gemcitabine compared to surgery alone, the recently reported ESPAC-3 trial was a direct comparison of gemcitabine to 5-FU in the adjuvant setting. This trial randomized patients with completely resected pancreatic carcinoma to 6 cycles of gemcitabine versus 6 cycles of 5-FU. In this adjuvant trial where patients did not receive RT by design, direct comparison of gemcitabine versus 5-FU demonstrated no significant difference in survival. 3 Although RTOG 9704 represents the only other phase III trial making a direct comparison of gemcitabine to 5-FU in the adjuvant setting, all patients received CRT by design.
When viewed in total, the findings from RTOG 9704, CONKO-001, and ESPAC-3, as well as previously reported phase III postoperative adjuvant therapy trials for pancreatic adenocarcinoma, would suggest the following: (1) the survival benefit associated with gemcitabine is observed with use of 6 cycles; (2) the survival benefit seen with gemcitabine in comparison to 5-FU appears to be temporary/marginal at best and seen only with the inclusion of CRT; (3) although the local recurrence rate of 28% seen in RTOG 9704, which made use of central RT QA, is the lowest reported to date and is approximately half of that reported in previous phase III adjuvant CRT trials, distant disease relapse remains the primary mode of failure, occurring in [70%. 10, 11, 21, 23 These fundamental observations, which are based on level 1 evidence, serve as the basis of the international EORTC/U.S. Intergroup/RTOG 0848 which is a phase III trial evaluating adjuvant therapy in patients with resected pancreatic adenocarcinoma, the schema of which is shown in Fig. 2 . Patient stratification will include CA19-9 level (\90 vs. [90-180). By design this trial will have 2 randomizations. The first randomization will evaluate the impact of the addition of erlotinib to gemcitabine. The testing of erlotinib is based on results in the locally advanced and metastatic setting demonstrating a survival benefit with use of erlotinib in combination with gemcitabine. 24 After 5 cycles of gemcitabine-based therapy, patients will undergo repeat imaging, and those who have no evidence of disease progression will undergo a second randomization evaluating the impact of CRT. CRT will be provided after completion of the sixth and final cycle of gemcitabine. During this sixth and final cycle, central RT QA will be performed. This trial will also allow the use of intensity-modulated RT in addition to transatlantic central RT QA. Quality of life, patient-reported outcomes, and correlative molecular science analyses are also planned.
